SVNS — Solvonis Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Solvonis Therapeutics Signs MoU With Portugal's National Addiction Institute
Solvonis Therapeutic - MOU Reached with ICAD
RCS - Solvonis Therapeutic - Investor Webinar – 15 October 2026
Solvonis Therapeutic - Unaudited interim results
Solvonis Therapeutic - New Analysis Identifies Major AUD Breakthrough
Solvonis Therapeutic - Vital Patent milestone achieved– SVN 114
Brief: Solvonis Therapeutics Raises £1.30 Mln Via Placing Of 1.08 Bln Shares At £0.0012 Each
Solvonis Therapeutic - Solvonis Raises £1.3 Million
RCS - Solvonis Therapeutic - Solvonis to Present at WTR Conference
Solvonis Therapeutic - SVN-015 Advances into Further NIDA-Funded Studies
RCS - Solvonis Therapeutic - Research Coverage Initiation
Brief: Solvonis Therapeutics Plans IND Submission For Phase 2B Trial Of SVN-2 In U.S.
Solvonis Therapeutic - Announces Positive Bridging Data Supporting
Solvonis Therapeutic - Notice of Annual General Meeting
RCS - Solvonis Therapeutic - CSO Speaks at National Research Meeting
Solvonis Therapeutic - Final Results
RCS - Solvonis Therapeutic - Appointment of Water Tower Research
RCS - Solvonis Therapeutic - US CNS Executive Order
Brief: Solvonis Therapeutics Says SVN-114 Selected As Lead Candidate For PTSD Discovery Programme